Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;63(2):2400067.
doi: 10.1183/13993003.00067-2024. Print 2024 Feb.

Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Anna J Podolanczuk  1 , Kerri I Aronson  2
Affiliations
Editorial

Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Anna J Podolanczuk et al. Eur Respir J. .

Abstract

Treatment with nintedanib slows the worsening of dyspnoea and fatigue, stabilises the degree of impact of pulmonary fibrosis, and may actually improve cough https://bit.ly/3S01WbX

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.J. Podolanczuk reports consulting fees from Veracyte, Imvaria, Regeneron, United Therapeutics, Eisai, Puretech and Boehringer Ingelheim, outside the submitted work. K.I. Aronson has no potential conflicts of interest to declare.

Comment on

References

    1. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092. - PubMed
    1. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769. - PubMed
    1. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082. - PubMed
    1. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727. - PubMed
    1. Raghu G, Ghazipura M, Fleming TR, et al. Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on “feels, functions, survives”. Am J Respir Crit Care Med 2024; in press [10.1164/rccm.202312-2213SO]. - DOI - PubMed

LinkOut - more resources